To assist potential prescribers the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Public Information Report on Sativex®, which can be found on the MHRA website.
Sativex® remains an unlicensed medicine in the UK and, as a cannabis-based medicine, is currently a Schedule 1 Controlled Drug. Previously doctors were required to obtain a licence to prescribe Sativex® from the Home Office but this is no longer a requirement as the Home Office has issued an open general licence permitting any doctor wishing to prescribe Sativex® to do so under the Misuse of Drugs Act. This licence also permits pharmacists to dispense Sativex® and permits patients to possess Sativex® if dispensed in accordance with a bona fide prescription.
As an unlicensed medicine, the decision to prescribe Sativex® for a patient is entirely at the discretion of the prescribing doctor and at their direct responsibility.
If you are a doctor in the UK and would like further information on Sativex® please contact either GW Pharmaceuticals or Bayer Healthcare using the details below:
GW Pharmaceuticals Tel: 01980 557026 Fax: 01980 557027 Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Bayer Healthcare Tel (during working hours): 01635 563 116 Tel (out of working hours): 01635 563 000 Fax: 01635 563 657 Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Latest News 
